Dexfenfluramine and the oestrogen-metabolizing enzyme CYP1B1 in the development of pulmonary arterial hypertension

Cardiovascular Research

Volumn 99, Issue 1, 2013, Pages 24-34

  Dempsie, Yvonne ^a   Macritchie, Neil A ^a   White, Kevin ^a   Morecroft, Ian ^a   Wright, Audrey F ^a   Nilsen, Margaret ^a   Loughlin, Lynn ^a   Mair, Kirsty M ^a   MacLean, Margaret R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

CYP1B1; Dexfenfluramine; Oestrogen; Pulmonary arterial hypertension; Tryptophan hydroxylase

Indexed keywords

ANOREXIGENIC AGENT; CYTOCHROME P450 1B1; DEXFENFLURAMINE; ESTRADIOL; ESTROGEN; SEROTONIN; TRYPTOPHAN HYDROXYLASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; ESTROGEN METABOLISM; FEMALE; HEART RIGHT VENTRICLE PRESSURE; MALE; MOUSE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; PULMONARY ARTERY; PULMONARY HYPERTENSION; SEROTONINERGIC SYSTEM; SMOOTH MUSCLE FIBER;

CYP1B1; DEXFENFLURAMINE; OESTROGEN; PULMONARY ARTERIAL HYPERTENSION; TRYPTOPHAN HYDROXYLASE;

ANIMALS; ARTERIAL PRESSURE; ARYL HYDROCARBON HYDROXYLASES; CELL PROLIFERATION; CELLS, CULTURED; DEXFENFLURAMINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; ESTRADIOL; FEMALE; HYPERTENSION, PULMONARY; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NORFENFLURAMINE; OVARIECTOMY; PULMONARY ARTERY; SEROTONIN; SEX FACTORS; TRYPTOPHAN HYDROXYLASE; VENTRICULAR FUNCTION, RIGHT; VENTRICULAR PRESSURE;

EID: 84879389539     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt064     Document Type: Article

References (46)

1. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173:1023-1030
2. Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007;30:104-109 (Pubitemid 47074013)
3. Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J 2007;30:1103-1110
4. Dempsie Y, Nilsen M, White K, Mair KM, Loughlin L, Ambartsumian N et al. Development of pulmonary arterial hypertension in mice over-expressing S100A4/Mts1 is specific to females. Respir Res 2011;12:159
5. White K, Dempsie Y, Nilsen M, Wright AF, Loughlin L, MacLean MR. The serotonin transporter, gender, and 17beta oestradiol in the development of pulmonary arterial hypertension. Cardiovasc Res 2011;90:373-382
6. Hanna IH, Dawling S, Roodi N, Guengerich FP, Parl FF. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res 2000;60:3440-3444 (Pubitemid 30482162)
7. Badawi AF, Cavalieri EL, Rogan EG. Role of human cytochrome P450 1A1, 1A2, 1B1, and 3A4 in the 2-, 4-, and 16alpha-hydroxylation of 17beta-estradiol. Metabolism 2001;50:1001-1003 (Pubitemid 32904154)
8. Murray GI, Taylor MC, McFadyen MC, McKay JA, Greenlee WF, Burke MD et al. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 1997;57: 3026-3031 (Pubitemid 27315056)
9. Laroche-Clary A, Le Morvan V, Yamori T, Robert J. Cytochrome P450 1B1 gene polymorphisms as predictors of anticancer drug activity: studies with in vitro models. Mol Cancer Ther 2010;9:3315-3321
10. Stoilov I, Akarsu AN, Sarfarazi M. Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. Hum Mol Genet 1997;6:641-647 (Pubitemid 27142117)
11. Jennings BL, Sahan-Firat S, Estes AM, Das K, Farjana N, Fang XR et al. Cytochrome P450 1B1 contributes to angiotensin II-induced hypertension and associated pathophysiology. Hypertension 2010;56:667-674
12. West J, Cogan J, Geraci M, Robinson L, Newman J, Phillips JA et al. Gene expression in BMPR2 mutation carriers with and without evidence of Pulmonary Arterial Hypertension suggests pathways relevant to disease penetrance. BMC Med Genomics 2008;1:45
13. Johnson JA, Hemnes AR, Perrien DS, Schuster M, Robinson LJ, Gladson S et al. Cytoskeletal defects in Bmpr2-associated pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2012;302:L474-L484
14. White K, Johansen AK, Nilsen M, Ciuclan L, Wallace E, Paton L et al. Activity of the estrogen metabolising enzyme cytochrome P450 1B1 influences the development of pulmonary arterial hypertension. Circulation 2012;126:1087-1098
15. White K, Loughlin L, Maqbool Z, Nilsen M, McClure J, Dempsie Y et al. Serotonin transporter, sex, and hypoxia: microarray analysis in the pulmonary arteries of mice identifies genes with relevance to human PAH. Physiol Genomics 2011;43: 417-437
16. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X et al. Appetitesuppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;335:609-616 (Pubitemid 26277950)
17. Kramer MS, Lane DA. Aminorex, dexfenfluramine, and primary pulmonary hypertension. J Clin Epidemiol 1998;51:361-364 (Pubitemid 28156054)
18. Rothman RB, Ayestas MA, Dersch CM, Baumann MH. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates - implications for primary pulmonary hypertension. Circulation 1999;100:869-875 (Pubitemid 29398887)
19. Dempsie Y, Morecroft I, Welsh DJ, Macritchie NA, Herold N, Loughlin L et al. Converging evidence in support of the serotonin hypothesis of dexfenfluramine-induced pulmonary hypertension with novel transgenic mice. Circulation 2008;117:2928-2937 (Pubitemid 351787078)
20. Chin KM, Channick RN, Rubin LJ. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest 2006;130:1657-1663 (Pubitemid 46033416)
21. Savale L, Chaumais MC, Cottin V, Bergot E, Frachon I, Prevot G et al. Pulmonary hypertension associated with benfluorex exposure. Eur Respir J 2012;40:1164-1172
22. Buters JT, Doehmer J, Gonzalez FJ. Cytochrome P450-null mice. Drug Metab Rev 1999;31:437-447 (Pubitemid 29222671)
23. Morecroft I, Pang L, Baranowska M, Nilsen M, Loughlin L, Dempsie Y et al. In vivo effects of a combined 5-HT1B receptor/SERT antagonist in experimental pulmonary hypertension. Cardiovasc Res 2010;85:593-603
24. Hong ZG, Olschewski A, Reeve HL, Nelson DP, Hong FX, Weir EK. Nordexfenfluramine causes more severe pulmonary vasoconstriction than dexfenfluramine. Am J Physiol Lung Cell Mol Physiol 2004;286:L531-L538 (Pubitemid 38233624)
25. Tofovic SP, Zhang XC, Jackson EK, Dacic S, Petrusevska G. 2-Methoxyestradiol mediates the protective effects of estradiol in monocrotaline-induced pulmonary hypertension. Vasc Pharmacol 2006;45:358-367 (Pubitemid 44765298)
26. Austin ED, Cogan JD, West JD, Hedges LK, Hamid R, Dawson EP et al. Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females. Eur Respir J 2009;34:1093-1099
27. Rothman RB, Cadet JL, Dersch CM, McCoy MT, Lehrmann E, Becker KG et al. Altered gene expression in pulmonary tissue of tryptophan hydroxylase-1 knockout mice: implications for pulmonary arterial hypertension. PLoS ONE 2011;6:e17735
28. Dempsie Y, MacLean MR. Pulmonary hypertension: therapeutic targets within the serotonin system. Br J Pharmacol 2008;155:455-462
29. MacLean MR. Pulmonary hypertension and the serotonin hypothesis: where are we now? Int J Clin Pract Suppl 2007;156:27-31
30. Weir EK, Reeve HL, Huang JMC, Michelakis E, Nelson DP, Hampl V et al. Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation 1996;94:2216-2220 (Pubitemid 26360516)
31. Reeve HL, Archer SL, Soper M, Weir EK. Dexfenfluramine increases pulmonary smooth muscle intracellular Ca2+ independent of membrane potential. Am J Physiol Lung Cell Mol Physiol 1999;277:L662-L666 (Pubitemid 29459687)
32. Higenbottam T, Marriott H, Cremona G, Laude E, Bee D. The acute effects of dexfenfluramine on human and porcine pulmonary vascular tone and resistance. Chest 1999; 116:921-930 (Pubitemid 29491860)
33. Lee SL, Wang WW, Fanburg BL. Dexfenfluramine as a mitogen signal via the formation of superoxide anion. FASEB J 2001;15:1324-1325
34. Rothman RB, Baumann MH. Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol Ther 2002;95:73-88
35. Launay JM, Herve P, Peoc'h K, Tournois C, Callebert J, Nebigil CG et al. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 2002;8:1129-1135 (Pubitemid 35175968)
36. Hironaka E, Hongo M, Sakai A, Mawatari E, Terasawa F, Okumura N et al. Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Cardiovasc Res 2003;60:692-699 (Pubitemid 37501127)
37. Rosselli M, Imthurm B, Macas E, Keller PJ, Dubey RK. Circulating nitrite/nitrate levels increase with follicular development: indirect evidence for estradiol-mediated NO release. Biochem Biophys Res Commun 1994;202:1543-1552
38. Archer SL, Djaballah K, Humbert M, Weir KE, Fartoukh M, Dall'ava-Santucci J et al. Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension. Am J Respir Crit Care Med 1998;158:1061-1067 (Pubitemid 28489002)
39. Humbert M, Deng Z, Simonneau G, Barst RJ, Sitbon O,Wolf M et al. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur Respir J 2002;20:518-523
40. Simonneau G, Fartoukh M, Sitbon O, Humbert M, Jagot JL, Herve P. Primary pulmonary hypertension associated with the use of fenfluramine derivatives. Chest 1998; 114(3 suppl):195S-199S (Pubitemid 28435967)
41. Lahm T, Albrecht M, Fisher AJ, Selej M, Patel NG, Brown JA et al. 17beta-Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects. Am J Respir Crit Care Med 2012;185:965-980
42. Tofovic PS, Zhang X, Petrusevska G. Progesterone inhibits vascular remodeling and attenuates monocrotaline-induced pulmonary hypertension in estrogen-deficient rats. Prilozi 2009;30:25-44
43. MacLean MR, DeucharGA,Hicks MN,Morecroft I, Shen SB, Sheward J et al. Overexpression of the 5-hydroxytryptamine transporter gene - effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension. Circulation 2004;109:2150-2155 (Pubitemid 38620226)
44. Tada Y, Majka S, Carr M, Harral J, Crona D, Kuriyama T et al. Molecular effects of loss of BMPR2 signaling in smooth muscle in a transgenic mouse model of PAH. Am J Physiol Lung Cell Mol Physiol 2007;292:L1556-L1563 (Pubitemid 47077371)
45. Weng M, Raher MJ, Leyton P, Combs TP, Scherer PE, Bloch KD. Adiponectin decreases pulmonary arterial remodeling in murine models of pulmonary hypertension. Am J Respir Cell Mol Biol 2011;45:340-347
46. Hemnes AR, Maynard KB, Champion HC, Gleaves L, Penner N, West J. Testosterone negatively regulates right ventricular load stress responses in mice. Pulm Circ 2012;2: 352-358.